Strides Pharma Science Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/80lk22ykr4baf7yxyf6l6gez.pdf

Key Takeaways


US Business: The $400 Million Roadmap

Arun Kumar: "I am saying that if we want to do a calibrated disciplined approach for the US business, in spite of us having so much of approved pipeline, we will believe that $400 million is the right size for us to keep the margin profile that we currently achieve in the US, and also to have a backup when we are challenged on certain products."

OneSource CDMO & the GLP-1 Opportunity


Other Regulated & Growth Markets


Balance Sheet & Cost Structure

Arun Kumar: "We don't believe our OPEX levels are going to increase greater than $200 million for several years. And that is because of our very keen focus on costs and also a lot of things that we do in terms of optimization, OPEX leverage, and OEE improvements in our plants."

Margins & Profitability

Arun Kumar: "We firmly stand by our guidance that in spite of about 150 crores of EBITDA moving to OneSource, we will still achieve our current EBITDA. So, effectively, we are telling you that like to like, our EBITDA will be closer to 950 crores in the next year."

Guidance & Commitments

CommitmentSpecificsTimeline
US revenue$240 million to $250 million; confident of higher endFY24
US business milestoneCloser to $400 millionWithin 2 financial years
Net debt to EBITDAUnder 3xFY24
Net debt to EBITDAMuch below 2xWithin 2 years
OneSource CDMO revenueApproximately $160 million at launch, $400 million targetLaunch year post-NCLT; FY27
Stelis JV lossesNegligible in H2; business turns EBITDA positiveH2 FY24
Syngene transaction closeExpected this quarterCurrent quarter
OPEX ceilingNot to exceed $200 millionFor several years
Like-to-like EBITDACloser to ₹950 croresNext year
Inventory daysReduce by another 15 days from 127Not specified
Top-line growth15% to 16% without incremental working capitalNot specified
Other regulated markets mirror US$400 millionProbably 4 to 4.5 years
US growth capMay not grow beyond $400 million to protect marginsAfter $400 million milestone

Key Metrics

MetricQ2 FY24
RevenueAll-time high, business grew 16%
Gross marginClose to 60%, almost industry high considering no domestic business
EBITDASixth consecutive quarter of absolute EBITDA growth
Other income₹26.9 cr, income earned on IPs in normal course of business, not a one-off
Net debt to EBITDA~3.3x, improved from 5.3x at FY23 end and ~8x at FY22 start
Net debt reduction₹62 cr from Singapore sale proceeds
Cash-to-cash cycleJust under 125–126 days, reduced by ~30 working days from FY22
US revenue guidance FY24$240 mn to $250 mn, confident of achieving higher end of $250 mn
US business exit run rateClose to $270 mn to $280 mn
US business milestone$400 mn, not later than 2 financial years from now
Other regulated markets exit run rate~$200 mn, almost 50% growth in last 2 years
OPEX levelsNot greater than $200 mn for several years
Personal cost new base₹185 cr, steady state going forward except standard annual increases
One-off cost increase in other OPEX₹15 cr, related to variable pay policy change for employees
Singapore facility sale margin improvementClose to ₹70 cr from EBITDA to PAT
Like-to-like EBITDA guidance next yearCloser to ₹950 cr, in spite of ~₹150 cr EBITDA moving to OneSource
CDMO business (OneSource) launch year revenueAbout $160 mn, next year after NCLT process
CDMO business (OneSource) FY27 target$400 mn
GLP-1 peak revenuesAbout $300 mn, dependent on partner approvals and patent regime
Products with $20 mn+ exit run rates3–4 products by end of year
Icosapent product opportunityAbout $20 mn by default of market size
Average product rangeMore than $10 mn to $12 mn, up from $4 mn–$5 mn historically
Inventory days127 days, down from 150-odd days; target to reduce by another 15 days
Top line growth expectation15% to 16% without worrying about incremental working capital
Targeted debt reduction Strides plus StelisAbout ₹700 cr
Debt to EBITDA target next 2 yearsMuch below 2